What also speaks in our favour is the short-term treatment compared to cancer patients; our model suggests only blocking the MEK/ERK1/2 pathway early (dosing during the first 24 h only), while in cancer therapy, dosing lasts for many months. This evidence concerns the gene MAPK3 and cancer.